Genotypic drug resistance interpretation systems--the cutting edge of antiretroviral therapy - PubMed (original) (raw)
Review
. 2002 Jul-Sep;4(3):148-56.
Affiliations
- PMID: 12416449
Review
Genotypic drug resistance interpretation systems--the cutting edge of antiretroviral therapy
Barbara Schmidt et al. AIDS Rev. 2002 Jul-Sep.
Erratum in
- AIDS Rev. 2003 Jan-Mar;5(1):63
Abstract
The technical quality of genotypic and phenotypic drug resistance testing has considerably improved, and therefore the major challenge now lies in the interpretation of drug resistance. This is due to several facts: (i) in times of combination therapy, the effect of drug resistance-associated mutations cannot be considered independently, (ii) many additive and subtractive interactions between mutations exist, and resistant strains may exhibit varying degrees of cross-resistance, (iii) the phenotype cannot adequately determine slight, but clinically relevant, differences for those drugs with a narrow range of resistance, and (iv) pharmacokinetic interactions may shift relevant levels of drug resistance. Genotypic drug resistance interpretation systems are designed to solve these problems. Rule-based systems incorporate current knowledge about correlations between genotype, phenotype and clinical response. Database-driven systems use the information provided by paired geno- and phenotypic data, applying database matching search or bioinformatic approaches. For detailed comparison, 11 interpretation systems were selected which present a comprehensive system for most of the available drugs, can easily be accessed via the Internet and are regularly updated. The systems were characterized for the source data, access, input, output, and availability of clinical studies. For further comparison, existing clinical databases should be merged into one large database to allow competition between the systems. This may also solve the burning problem of clinically relevant cut-offs. Head-to-head comparisons of interpretation systems require large prospective randomized trials in which only the interpretation system is different between groups, before a consensus can be achieved for the best antiretroviral therapy of the individual patient.
Similar articles
- Analysis of discrepancies in the interpretation of antiretroviral drug resistance results in HIV-1 infected patients of Basque Country, Spain.
Muñoz M, Carmona R, Pérez-Alvarez L, Cilla G, Suarez MD, Delgado E, Contreras G, Corral J, de Goicoetxea MJ, Medrano L, Lezaún MJ, Nájera R; Spanish Group for Antiretroviral Resistance Studies in Basque Country. Muñoz M, et al. J Clin Virol. 2005 Jul;33(3):224-9. doi: 10.1016/j.jcv.2004.06.014. Epub 2005 Jan 12. J Clin Virol. 2005. PMID: 15911444 - Algorithms for the interpretation of HIV-1 genotypic drug resistance information.
Vercauteren J, Vandamme AM. Vercauteren J, et al. Antiviral Res. 2006 Sep;71(2-3):335-42. doi: 10.1016/j.antiviral.2006.05.003. Epub 2006 May 30. Antiviral Res. 2006. PMID: 16782210 Review. - Construction, training and clinical validation of an interpretation system for genotypic HIV-1 drug resistance based on fuzzy rules revised by virological outcomes.
De Luca A, Vendittelli M, Baldini F, Di Giambenedetto S, Trotta MP, Cingolani A, Bacarelli A, Gori C, Perno CF, Antinori A, Ulivi G. De Luca A, et al. Antivir Ther. 2004 Aug;9(4):583-93. Antivir Ther. 2004. PMID: 15456090 - Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy.
Hanna GJ, D'Aquila RT. Hanna GJ, et al. Clin Infect Dis. 2001 Mar 1;32(5):774-82. doi: 10.1086/319231. Epub 2001 Feb 28. Clin Infect Dis. 2001. PMID: 11229846 Review. - Interpreting resistance data for HIV-1 therapy management--know the limitations.
Van Laethem K, Vandamme AM. Van Laethem K, et al. AIDS Rev. 2006 Jan-Mar;8(1):37-43. AIDS Rev. 2006. PMID: 16736950 Review.
Cited by
- Transmitted drug resistance in nonsubtype B HIV-1 infection.
Chan PA, Kantor R. Chan PA, et al. HIV Ther. 2009 Sep 1;3(5):447-465. doi: 10.2217/hiv.09.30. HIV Ther. 2009. PMID: 20161523 Free PMC article. - Partial inhibition of human immunodeficiency virus replication by type I interferons: impact of cell-to-cell viral transfer.
Vendrame D, Sourisseau M, Perrin V, Schwartz O, Mammano F. Vendrame D, et al. J Virol. 2009 Oct;83(20):10527-37. doi: 10.1128/JVI.01235-09. Epub 2009 Aug 12. J Virol. 2009. PMID: 19706714 Free PMC article. - Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1.
Zhang H, Zhou Y, Alcock C, Kiefer T, Monie D, Siliciano J, Li Q, Pham P, Cofrancesco J, Persaud D, Siliciano RF. Zhang H, et al. J Virol. 2004 Feb;78(4):1718-29. doi: 10.1128/jvi.78.4.1718-1729.2004. J Virol. 2004. PMID: 14747537 Free PMC article. - Search algorithms as a framework for the optimization of drug combinations.
Calzolari D, Bruschi S, Coquin L, Schofield J, Feala JD, Reed JC, McCulloch AD, Paternostro G. Calzolari D, et al. PLoS Comput Biol. 2008 Dec;4(12):e1000249. doi: 10.1371/journal.pcbi.1000249. Epub 2008 Dec 26. PLoS Comput Biol. 2008. PMID: 19112483 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical